Lulu Zhu

Lulu Zhu

Auto-generated profile, based on publicly available information

Lulu Zhu

School of Public Health of Guangxi Medical University, Nanning, Guangxi, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MHMeixi Hao
Meixi Hao
SHSiyuan Hou
Siyuan Hou
WLWeishuo Li
Weishuo Li
KLKaiming Li
Kaiming Li
LXLingjing Xue
Lingjing Xue
CZCan Zhang
Can Zhang
Treatment of solid tumors with T cell therapy has yielded limited therapeutic benefits to date. Although T cell therapy in combination with proinflammatory cytokines or immune checkpoints inhibitors has demonstrated preclinical and clinical successes in a subset of solid tumors, unsatisfactory results and severe toxicities necessitate the development of effective and safe combinatorial strategies. Here, the liposomal avasimibe (a metabolism-modulating drug) was clicked onto the T cell surface by lipid insertion without disturbing the physiological functions of the T cell. Avasimibe could be restrained on the T cell surface during circulation and extravasation and locally released to increase the concentration of cholesterol in the T cell membrane, which induced rapid T cell receptor clustering and sustained T cell activation. Treatment with surface anchor-engineered T cells, including mouse T cell receptor transgenic CD8+ T cells or human chimeric antigen receptor T cells, resulted in superior antitumor efficacy in mouse models of melanoma and glioblastoma. Glioblastoma was completely eradicated in three of the five mice receiving surface anchor-engineered chimeric antigen receptor T cells, whereas mice in other treatment groups survived no more than 64 days. Moreover, the administration of engineered T cells showed no obvious systemic side effects. These cell-surface anchor-engineered T cells hold translational potential because of their simple generation and their safety profile.

1 February 2021 in Neuroscience Letters
Verified
Journal Article
Closed access
LZLulu Zhu
Lulu Zhu
XWXulong Wu
Xulong Wu
BXBingyi Xu
Bingyi Xu
ZZZhi Zhao
Zhi Zhao
JYJialei Yang
Jialei Yang
LSLi Su
Li Su